Financial Performance - For the year ended December 31, 2023, the company's revenue was RMB 933.1 million, representing a year-on-year increase of 46.6% compared to RMB 636.5 million for the year ended December 31, 2022[14]. - The group recorded a profit of RMB 132.1 million for the year ending December 31, 2023, compared to a loss of RMB 291.6 million in 2022, primarily due to a recovery in business performance and a significant increase in pediatric services[16]. - The gross profit margin for medical services improved to 44.2% in 2023 from 32.3% in 2022, with gross profit rising to RMB 407.8 million from RMB 203.6 million[24]. - The profit attributable to the owners of the company for the year ended December 31, 2023, was RMB 84.2 million, compared to a loss of RMB 297.7 million for the year ended December 31, 2022[44]. - The company’s financial performance for the year ending December 31, 2023, is detailed in the comprehensive income statement section of the annual report[111]. Revenue Sources - Revenue from medical services for the year ended December 31, 2023, was RMB 922.8 million, up 46.5% from RMB 629.8 million in the previous year, accounting for 98.9% of total revenue[14]. - Pediatric services contributed 87.8% and obstetric services contributed 11.1% to the total revenue for the year ended December 31, 2023[14]. - Revenue from pediatric services accounted for 87.8% of total medical service revenue in 2023, up from 83.7% in 2022, while obstetric services contributed 11.1%, down from 15.3%[26]. - Pediatric internal medicine revenue grew by 102.2% year-on-year, becoming a major driver of the group's performance growth[18]. Operational Metrics - The number of outpatient visits increased by 40.7% to 337,351 in 2023, with pediatric outpatient visits rising by 47.6% to 289,375[11]. - The number of inpatient visits grew by 27.1% to 9,097, with pediatric inpatient visits increasing by 38.0% to 7,432[11]. - The company served nearly 480,000 families and approximately 350,000 patient visits in 2023[9]. - The total revenue from medical services reached RMB 922.8 million in 2023, representing a year-on-year growth of 46.5%, accounting for 98.9% of the group's total revenue[28]. Cost and Expenses - The cost of revenue for medical services was RMB 514.9 million, reflecting a year-on-year increase of 20.8%, consistent with the growth in revenue from outpatient and inpatient services[29]. - Research and development expenses decreased to RMB 5.9 million in 2023 from RMB 7.7 million in 2022, primarily due to reduced R&D activities[35]. - Administrative expenses decreased by 1.4% to RMB 129.9 million in 2023, attributed to the closure of loss-making clinics and optimization of personnel structure[34]. - Sales expenses rose by 9.6% to RMB 68.3 million in 2023, primarily due to increased personnel costs and miscellaneous expenses associated with business growth[32]. Strategic Initiatives - The company plans to continue expanding its pediatric and obstetric services, focusing on high-end services and improving critical care levels[8]. - The group plans to enhance its strategic focus on sub-specialty development in pediatrics and obstetrics, aiming to expand services in pediatric ophthalmology, child healthcare, and endocrinology[23]. - The company aims to leverage national policy opportunities to expand its business and contribute to the health strategy of China[12]. - The company is developing innovative medical services such as children's growth and development management packages, which have received positive customer feedback[11]. Management and Governance - Jason Zhou has been the CEO and Chairman since August 2015, leading the company in the private healthcare sector for over 21 years[71]. - The company has a strong management team with extensive experience in hospital operations and financial management, including CFO Xu Han who oversees financial activities and internal controls[75]. - The board consists of eleven members, including Jason Zhou as Chairman and CEO, and Xin Hong as COO[194]. - The company has adhered to the corporate governance code, except for the separation of the roles of Chairman and CEO, which are held by the same individual[192]. Shareholder Information - As of December 31, 2023, the company's share premium balance is RMB 2,606.5 million, available for distribution to shareholders[113]. - The board has proposed a final dividend of HKD 0.0378 per share for the year ended December 31, 2023, totaling HKD 18,523,000, compared to no dividend for the previous year[183]. - The company has maintained sufficient public float as per listing rules as of December 31, 2023[189]. Compliance and Risk Management - The company has complied with all relevant environmental laws and regulations in 2023, ensuring proper handling of medical waste and emissions[108]. - The company’s financial risk management objectives and policies are detailed in the consolidated financial statements[98]. - The company’s business operations are subject to compliance with laws and regulations in mainland China, the Cayman Islands, and Hong Kong[109]. Future Outlook - The company has outlined a future outlook with a projected revenue growth of 20% for the upcoming fiscal year[90]. - The company is expanding its market presence by entering three new regions, aiming to increase its market share by 10%[90]. - A strategic acquisition of a local healthcare provider is in progress, which is anticipated to add $50 million in annual revenue[90].

Revenue and Profitability - For the year ended December 31, 2023, the total revenue generated from medical services accounted for 98.9% of the company's total revenue, with pediatric services contributing 87.8% and obstetric services contributing 11.1%[9]. - Total revenue for the year ended December 31, 2023, was RMB 922.8 million, up from RMB 629.8 million in 2022, representing a year-on-year increase of approximately 46.5%[16]. - The company recorded a profit of RMB 132.1 million for the year ended December 31, 2023, a significant recovery from a loss of RMB 291.6 million in the previous year, primarily due to improved business performance in pediatric services[11]. - The group reported a net profit of RMB 132,089,000 for the year, compared to a net loss of RMB 291,573,000 in the previous year[38]. - The company reported a profit attributable to shareholders of RMB 84.2 million in 2023, compared to a loss of RMB 297.7 million in 2022, resulting in a basic earnings per share of RMB 0.17[132]. - The company achieved a profit before tax of approximately RMB 166.1 million for the year ended December 31, 2023, compared to a loss before tax of approximately RMB 289.9 million for the previous year, primarily due to a gross profit increase of RMB 205.0 million or 101.4%[91]. Revenue Breakdown - Revenue from obstetric services increased by 6.8% year-on-year to RMB 104.0 million, despite a 5.9% decrease in inpatient visits to 1,665 and a 7.6% decrease in inpatient medical service revenue to RMB 47.2 million[10]. - In pediatric services, inpatient visits increased to 9,097, with an average spending per inpatient of RMB 33,109, compared to 7,156 visits and RMB 29,434 in the previous year[37]. - Outpatient visits rose to 337,351, with an average spending per outpatient of RMB 1,693, up from 239,767 visits and RMB 1,556 in 2022[37]. - Outpatient medical service revenue reached RMB 571.2 million, a growth of 53.1% from RMB 373.2 million in the previous year, with outpatient visits increasing by 40.7% to 337,351[92]. - Inpatient medical service revenue was RMB 301.2 million, up 43.0% from RMB 210.6 million, with inpatient visits increasing by 27.1% to 9,097[92]. - Pediatric services revenue increased by 53.8% from RMB 532.4 million in 2022 to RMB 818.8 million in 2023, with inpatient visits rising by 38.0% to 7,432[116]. Financial Position - The total assets as of December 31, 2023, amounted to RMB 944,393,000, with total liabilities of RMB 492,634,000[38]. - Total liabilities decreased to RMB 492.6 million as of December 31, 2023, from RMB 540.0 million in the previous year[88]. - Total equity increased to RMB 451.8 million as of December 31, 2023, compared to RMB 361.4 million in the previous year[96]. - Non-current assets totaled RMB 500.9 million as of December 31, 2023, down from RMB 557.7 million in the previous year[96]. - The company maintained cash and cash equivalents of RMB 304,300,000 as of December 31, 2023, compared to RMB 226,100,000 in the previous year[51]. Expenses and Costs - The gross profit for the year ended December 31, 2023, was RMB 407.8 million, with a gross margin of 44.2%, compared to a gross profit of RMB 203.6 million and a gross margin of 32.3% in 2022[16]. - The cost of revenue for medical services was RMB 514.9 million in 2023, representing a year-on-year increase of 20.8%[124]. - The sales expenses for 2023 were RMB 68.3 million, up 9.6% year-on-year, primarily due to increased personnel costs and miscellaneous expenses[126]. - The administrative expenses decreased by 1.4% year-on-year to RMB 129.9 million, attributed to the closure of loss-making clinics and optimization of personnel structure[127]. - Research and development expenses for the year were RMB 5,930,000, a decrease from RMB 7,695,000 in 2022[38]. Corporate Governance and Compliance - The company has complied with all applicable corporate governance code provisions for the year ended December 31, 2023, except for the separation of the roles of Chairman and CEO[61]. - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring oversight of financial reporting[64]. - The company has established strict guidelines for securities trading by directors and employees, confirming compliance for the year ended December 31, 2023[62]. - The company is committed to maintaining high corporate governance standards as per the applicable principles of the corporate governance code[78]. Future Plans and Strategy - The company plans to continue optimizing its strategy and increasing the reserve of quality medical expert resources in 2024[12]. - The focus will be on sub-specialty development and establishing a product and service chain around customer medical and health needs, leveraging multi-disciplinary collaboration in pediatric and obstetric services[13]. - The company plans to expand its market presence in pediatric ophthalmology, pediatric healthcare, endocrinology, and dental services[140]. Shareholder Information - The company proposed a final dividend of HKD 0.0378 per share for the year ended December 31, 2023, totaling HKD 18,523,000, compared to no dividend for the previous year[58]. - The final dividend is subject to approval at the annual general meeting and is expected to be paid on or before July 2, 2024, if approved[75]. - The annual general meeting is scheduled for May 22, 2024, with the share register closing from May 17 to May 22, 2024, for voting eligibility[59]. Miscellaneous - The company has no significant investments, acquisitions, or disposals during the year ended December 31, 2023[160]. - The company has no significant events to disclose after the reporting period as of the annual performance announcement date[191]. - The company is a non-wholly owned subsidiary established in China, specifically Beijing New Century Children's Hospital, registered in December 2002[194]. - The company was incorporated in the Cayman Islands on July 31, 2015, and its shares are listed on the main board of the Hong Kong Stock Exchange[194].

Shareholding Structure - As of June 30, 2023, Jason ZHOU holds 217,556,394 shares, representing approximately 44.40% of the company's equity[5]. - JoeCare owns 150,817,051 shares, accounting for 30.8% of the company's equity[9]. - Victor Gains Limited holds 57,740,181 shares, which is 11.8% of the company's equity[9]. - The company has a total of 450,000 restricted shares granted to key personnel, with 180,000 shares vested under certain conditions[6]. - As of June 30, 2023, the company has purchased 2,073,500 shares under the Employee Share Scheme, held in trust for selected participants[17]. - The total number of shares available for grant under the Employee Share Scheme is 24,501,250, equivalent to 5% of the issued share capital as approved on August 28, 2020[17]. Financial Performance - The net profit attributable to the owners of the company for the six months ended June 30, 2023, was RMB 231 million, a significant recovery from a net loss of RMB 2,336 million in the same period of 2022[46]. - Revenue from medical services for the six months ended June 30, 2023, was RMB 4,111 million, reflecting a year-on-year growth of 48.5% and accounting for 98.8% of total revenue[57]. - The gross profit for the six months ended June 30, 2023, was RMB 1,698 million, an increase of 155.0% compared to the previous year, with a gross margin rising from 23.8% to 40.8%[59]. - The company reported a profit of RMB 44.1 million for the first half of 2023, a significant turnaround from a loss of RMB 234.7 million in the same period last year[86]. - Revenue for the six months ended June 30, 2023, was RMB 416,133 thousand, a significant increase from RMB 280,104 thousand in the same period of 2022, representing a growth of approximately 48.6%[132]. - Operating profit for the same period was RMB 64,551 thousand, compared to an operating loss of RMB 232,280 thousand in the prior year, indicating a turnaround in performance[132]. Revenue Breakdown - The obstetrics and gynecology business achieved revenue of RMB 532 million in the first half of 2023, representing a year-on-year growth of 14.9%[45]. - Outpatient service revenue reached RMB 282 million, with a year-on-year increase of 23.7%, and outpatient visits totaled 25,248, up 11.0%[45]. - Pediatric services revenue reached RMB 357.86 million, representing an 85.8% increase compared to RMB 230.56 million in the same period last year[69]. - Pediatric service revenue reached RMB 357.9 million, up 55.2% year-on-year, accounting for 87.1% of total medical service revenue[117]. - Inpatient services saw an increase in patient visits to 4,318 from 3,151, with average spending per inpatient rising to RMB 31,536 from RMB 29,516[77]. - Outpatient services recorded 154,487 visits, up from 111,164, with average spending per outpatient increasing to RMB 1,625 from RMB 1,495[77]. Cost and Expenses - The cost of medical services increased by 14.7% year-on-year to RMB 240.7 million[79]. - Administrative expenses decreased by 1.6% to RMB 635 million, attributed to a reduction in the number of operational clinics and optimization of personnel structure[101]. - Research and development expenses decreased to RMB 3.1 million from RMB 4.2 million year-on-year due to reduced R&D activities[83]. - Capital expenditures for the first half of 2023 amounted to RMB 2.5 million, primarily for property, plant, and equipment[92]. Cash Flow and Financial Position - Cash and cash equivalents as of June 30, 2023, were RMB 246.0 million, up from RMB 226.1 million at the end of 2022[89]. - Operating cash flow for the six months ended June 30, 2023, was RMB 62,911 thousand, compared to RMB 10,804 thousand in the same period of 2022, representing a significant increase[181]. - Net cash generated from operating activities was RMB 43,275 thousand, a turnaround from a net cash outflow of RMB (4,982) thousand in the previous year[181]. - Cash and cash equivalents at the end of the period increased to RMB 246,020 thousand from RMB 178,868 thousand in the prior year, reflecting a net increase of RMB 17,489 thousand[181]. Risk Management and Compliance - The company has implemented measures to enhance its risk management and internal control systems following compliance issues, indicating a strategic focus on governance[138]. - The company faces various financial risks, including market risk, credit risk, and liquidity risk, which are continuously monitored[165]. - The expected credit losses for trade receivables are assessed based on historical loss rates and external credit ratings, indicating a proactive approach to credit risk management[169]. - The company has not adopted any new accounting standards that would significantly impact its financial reporting as of June 30, 2023[165]. Corporate Governance - The board is committed to maintaining high corporate governance standards and has applied the principles of the corporate governance code[25]. - The company has confirmed compliance with the standards set forth in the Securities Trading Code by all directors as of June 30, 2023[32]. - The company has adopted a standard code for securities trading by directors and has established strict guidelines for employees[29]. Employee and Shareholder Information - The company had 1,252 employees as of June 30, 2023, a decrease from 1,303 employees a year earlier[136]. - The company declared dividends amounting to RMB 8,086 thousand during the reporting period, which is a reduction compared to previous distributions[156].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 1518 截至二零二三年六月三十日止六個月 中期業績公告 二零二三年中期業績摘要 以下載列我們截至二零二三年六月三十日止六個月的主要業績摘要： 1. 我們於截至二零二三年六月三十日止六個月錄得收益人民幣416.1百萬元， 與去年同期相比增加48.6%。 2. 期內除所得稅前溢利為人民幣63.8百萬元，而去年同期為除稅前虧損人 民幣233.6百萬元，主要原因是：(1)毛利增加人民幣103.2百萬元；(2)金融 資產減值虧損淨額減少人民幣109.1百萬元；及(3)非流動資產減值虧損 減少人民幣82.8百萬元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 1518 有關截至二零二二年十二月三十一日止年度的年度報告的補充公告 茲提述新世紀醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 截至二零二二年十二月三十一日止年度的年度報告（於二零二三年四月二十七 日在聯交所網站(www.hkexnews.hk)刊發，「二零二二年度報告」）。除另有界定 外，本公告內所用詞彙與二零二二年度報告內所界定者具有相同涵義。 除二零二二年度報告所提供的資料外，董事會謹此向股東及本公司潛在投資 者提供更多詳情，內容有關僱員股份計劃。於二零二二年十二月三十一日，僱 員股份計劃項下可供授出的本公司股份總數仍為24,501,250股，相當於董事會 在二零二零年八月二十八日所批准及採納的5%計劃限額。於二零二二年十二 月三十一日，計劃限額保持不變，仍為5%。 承董事會命 新世紀醫療控股有限公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 1518 有關截至二零二二年十二月三十一日止年度的年度報告的補充公告 及 有關向嘉華麗康提供財務資助的過往須予公佈交易及關連交易 茲提述新世紀醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 截至二零二二年十二月三十一日止年度的年度報告（於二零二三年四月二十七 日在聯交所網站(www.hkexnews.hk)刊發，「二零二二年度報告」）。除另有界定 外，本公告內所用詞彙與二零二二年度報告內所界定者具有相同涵義。 除二零二二年度報告所提供的資料外，董事會謹此向股東及本公司潛在投資 者提供更多詳情，內容有關(i)截至二零二二年十二月三十一日止年度的非流動 資產減值虧損；(ii)截至二零二二年十二月三十一日止年度的金融資產減值虧損； 及(iii)有關向嘉華麗康提供財務資助的過往須予公佈交易及關連交易。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 1518 有關截至二零二二年十二月三十一日止年度的年度報告的補充公告 及 有關向嘉華麗康提供財務資助的過往須予公佈交易及關連交易 茲提述新世紀醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 截至二零二二年十二月三十一日止年度的年度報告（於二零二三年四月二十七 日在聯交所網站(www.hkexnews.hk)刊發，「二零二二年度報告」）。除另有界定 外，本公告內所用詞彙與二零二二年度報告內所界定者具有相同涵義。 除二零二二年度報告所提供的資料外，董事會謹此向股東及本公司潛在投資 者提供更多詳情，內容有關(i)截至二零二二年十二月三十一日止年度的非流動 資產減值虧損；(ii)截至二零二二年十二月三十一日止年度的金融資產減值虧損； 及(iii)有關向嘉華麗康提供財務資助的過往須予公佈交易及關連交易。 ...

Financial Performance - New Century Healthcare reported a total revenue of RMB 10.4 million for the year ended December 31, 2022, which is a slight decrease from the annual cap of RMB 10.5 million[31]. - The company reported a total comprehensive loss attributable to owners of RMB 101,461,000 for the year, compared to a loss of RMB 85,262,000 in 2021, indicating a worsening financial performance[163]. - The net loss for the year was RMB 291,573 thousand, compared to a net loss of RMB 85,262 thousand in 2021, indicating a significant increase in losses[186]. - Basic and diluted loss per share for the year was RMB 0.62, compared to RMB 0.21 in the previous year, showing a deterioration in earnings per share[186]. - The accumulated losses increased significantly from RMB 371,592 thousand in 2021 to RMB 669,326 thousand in 2022, representing an increase of approximately 80.2%[159]. - Total revenue for the year ended December 31, 2022, was RMB 636,459 thousand, a slight increase from RMB 632,565 thousand in 2021, representing a growth of approximately 0.6%[186]. Corporate Governance - The company aims to maintain a high standard of corporate governance to enhance transparency and accountability in its business strategies[41]. - The company has complied with all applicable code provisions of the Corporate Governance Code, except for the separation of the roles of Chairman and CEO[68]. - The board currently consists of 12 members, with 3 women, resulting in a female representation of 25%[86]. - The company has a board diversity policy that considers various factors including professional qualifications, industry experience, and gender[79]. - The company aims to enhance gender diversity on the board and will continue to increase the proportion of female members as suitable candidates are identified[86]. - The nomination committee will monitor the implementation of the board diversity policy and review the composition of the board at least annually[108]. Audit and Compliance - The company’s independent auditors provided an unqualified opinion on the disclosed continuing related transactions[27]. - The company has appointed PwC as its auditor for the year ending December 31, 2022, and will propose their reappointment at the upcoming annual general meeting[67]. - All independent non-executive directors have confirmed their independence in writing according to listing rules[72]. - The audit committee held three meetings in 2022 to review interim and annual financial performance and significant matters related to financial reporting[100]. Financial Position - The total assets decreased from RMB 1,270,896 thousand in 2021 to RMB 901,384 thousand in 2022, representing a decline of approximately 29.1%[159]. - The company's total equity decreased from RMB 684,238 thousand in 2021 to RMB 361,351 thousand in 2022, a decline of about 47.3%[159]. - The total liabilities decreased to RMB 540,033 thousand in 2022 from RMB 586,658 thousand in 2021, reflecting a reduction of about 7.9%[184]. - Non-current liabilities decreased from RMB 295,481 thousand in 2021 to RMB 206,221 thousand in 2022, a reduction of approximately 30.2%[184]. - The total equity and liabilities amounted to RMB 901,384 thousand in 2022, down from RMB 1,270,896 thousand in 2021, a decrease of approximately 29.1%[184]. Operational Highlights - The company continues to focus on pediatric and obstetric specialty services in China, along with hospital consulting and online medical services[189]. - The company has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee to oversee its affairs[50]. - The Remuneration Committee held one meeting in 2022 to review the company's remuneration policies and provide recommendations to the board[51]. - The Nomination Committee also held one meeting in 2022 to review the structure and independence of the board[52]. Cash Flow and Investments - Operating cash flow for the year ended December 31, 2022, was RMB 106,550,000, an increase from RMB 62,700,000 in 2021, representing a growth of 69.9%[165]. - Net cash generated from operating activities was RMB 76,280,000, significantly up from RMB 22,255,000 in the previous year, indicating a substantial improvement in operational efficiency[165]. - The company incurred a net cash outflow from investing activities of RMB 23,068,000, compared to RMB 15,743,000 in the previous year, indicating increased investment activity[165]. Risk Management and Internal Controls - The company focuses on risk management and internal controls, emphasizing customer and employee safety, quality control, and general risk management[114]. - The company’s internal control processes are regularly reviewed and assessed for effectiveness, although they cannot guarantee the absolute prevention of significant errors or fraud[114]. - The company conducts annual impairment tests for goodwill and other intangible assets, adjusting for any identified impairments[122]. Asset Management - The company reported a goodwill impairment assessment as of December 31, 2022, indicating potential risks in asset valuation[143]. - The company utilized a sensitivity analysis to evaluate the impact of key assumptions on the recoverable amount of cash-generating units[145]. - The company’s management made significant judgments regarding expected credit loss estimates based on historical credit records and macroeconomic parameters[147].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部份內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 1518 截至二零二二年十二月三十一日止年度的年度業績公告 二零二二年度業績摘要 以下載列本集團截至二零二二年十二月三十一日止年度的主要業績摘要： 1. 我們於截至二零二二年十二月三十一日止年度錄得收益約人民幣636.5百萬元， 與二零二一年相比小幅增加0.6%。 2. 年內除所得稅前虧損增加至人民幣289.9百萬元，而去年為人民幣59.1百萬元， 主要原因是：(1)非流動資產減值虧損增加人民幣140.7百萬元；(2)於聯營公司 的投資的減值虧損增加人民幣7.9百萬元；及(3)金融資產減值虧損淨額增加人 民幣119.1百萬元。 主要經營數據 截至十二月三十一日 止年度 增長額╱ 二零二二年 二零二一年 （減少額） ...

Revenue Performance - The company's revenue for the first half of 2022 was RMB 280.1 million, a decrease of 2.0% year-on-year[12]. - Medical service revenue amounted to RMB 276.9 million, down 1.8% compared to the same period last year[12]. - The total revenue for the first half of 2022 was RMB 280.1 million, a decrease of 2.0% compared to RMB 285.8 million in the same period of 2021[25]. - Total revenue for the six months ended June 30, 2022, was RMB 280,104 thousand, a decrease of 2.6% compared to RMB 285,844 thousand for the same period in 2021[114]. - Total revenue for the six months ended June 30, 2022, was not explicitly stated but is implied to have decreased due to the reported losses and cash flow issues[127]. Pediatric Services - Pediatric service revenue increased by 4.3% year-on-year to RMB 230.6 million, accounting for 83.3% of total medical service revenue[16]. - Pediatric outpatient service revenue was RMB 143.4 million, an increase of 8.1%, while inpatient service revenue was RMB 69.5 million, a slight decrease of 0.4%[16]. - Pediatric services generated revenue of RMB 230.6 million, representing 82.3% of medical services revenue, an increase from 77.3% in the previous year[28]. - The contribution of pediatric specialty services to pediatric outpatient and inpatient revenue remained stable at 42.3%[12]. - The company continues to focus on pediatric and obstetric specialty services, as well as online medical services, indicating a strategic emphasis on expanding its service offerings[127]. Financial Losses - The company recorded a net loss of RMB 234.7 million for the six months ended June 30, 2022, primarily due to strict pandemic control measures and increased market competition[16]. - The loss for the six months ended June 30, 2022, was RMB 234.7 million, compared to a loss of RMB 49.1 million in the same period last year[47]. - The company reported a net loss of RMB 234,741 thousand for the six months ended June 30, 2022, compared to a net loss of RMB 49,141 thousand in the previous year[114]. - The company incurred a loss of RMB 605,240,000 for the six months ended June 30, 2022, compared to a loss of RMB 371,592,000 for the same period in 2021[120]. Expenses and Cost Management - The company's gross profit for the six months ended June 30, 2022, was RMB 66.6 million, a decrease of 11.4% year-on-year, with a gross margin dropping from 26.3% to 23.8%[35]. - Sales expenses increased by 17.3% year-on-year to RMB 32.5 million, primarily due to the expansion of the marketing team to recover revenue scale under ongoing pandemic control measures[36]. - Administrative expenses decreased by 7.1% to RMB 64.5 million, compared to RMB 69.4 million in the same period last year, due to enhanced operational management and cost-cutting measures[38]. - Research and development expenses were RMB 4.2 million, down from RMB 5.9 million in the previous year, mainly due to reduced R&D activities[39]. - The company aims to optimize its structure and talent management to strengthen cost control[22]. Asset and Liability Management - Total assets as of June 30, 2022, were RMB 1,016,893 thousand, down from RMB 1,270,896 thousand at the end of 2021, representing a decrease of 20%[112]. - Current liabilities increased to RMB 354,016 thousand from RMB 291,177 thousand, an increase of 21.5%[112]. - The company recorded a significant increase in financial asset impairment losses to RMB 115,352 thousand from RMB 1,035 thousand year-on-year[114]. - Trade receivables increased by 7.9% to RMB 42.5 million, driven by higher receivables from health insurance agencies[51]. - Inventory decreased by 11.4% to RMB 18.7 million from RMB 21.1 million as of December 31, 2021, due to increased stockpiling during peak medical service demand[50]. Shareholder Information - Major shareholders include JoeCare with a 30.8% stake and Victor Gains Limited with an 11.8% stake as of June 30, 2022[77]. - The company has a total of 150,817,051 shares held directly by Jason ZHOU, reflecting his ownership in the issued share capital[81]. - The company has 31,562,713 shares held by 博裕（上海）股權投資管理有限責任公司, representing approximately 6.4% of the company's equity[80]. - 中國人壽再保險有限責任公司 holds 31,444,000 shares, also accounting for about 6.4% of the company's equity[80]. - The employee share plan has resulted in the purchase of 2,073,500 shares, which are held in trust for selected participants[90]. Governance and Compliance - The company has adhered to all applicable corporate governance code provisions as of June 30, 2022, except for the separation of the roles of Chairman and CEO[97]. - The audit committee, consisting of two independent non-executive directors and one non-executive director, has reviewed the interim results for the six months ended June 30, 2022[101]. - The company confirms that there have been no significant changes in the information disclosed in the annual report compared to the current data as of June 30, 2022[102]. - The company has adopted a strict code of conduct for securities trading by directors and employees, with no violations reported as of June 30, 2022[98]. - The company has not disclosed any significant changes in director information since the last annual report[99]. Impairment and Credit Losses - The company recorded an impairment loss on non-current assets of RMB 82.8 million, including RMB 37.3 million for intangible assets and RMB 33.6 million for goodwill[40]. - Financial asset impairment losses amounted to RMB 115.4 million, primarily due to expected credit losses from receivables[43]. - The expected credit loss rate for trade receivables (third-party) is 0.86%, with a total book value of RMB 42,639 thousand and an expected credit loss of RMB 368 thousand[150]. - The expected credit loss rate for trade receivables from individual customers is 90.90%, with a total book value of RMB 2,120 thousand and an expected credit loss of RMB 1,927 thousand[150]. - The total expected credit loss across all categories amounts to RMB 234,055 thousand, with a net loss book value of RMB 129,474 thousand[150]. Future Plans and Strategies - The company aims to enhance its medical service model to meet the refined, professional, and personalized health development needs of new-generation families[11]. - The company plans to enhance customer management systems to improve customer experience and increase membership base[20]. - The company is strengthening market promotion and partnerships with insurance institutions to enhance customer coverage[21]. - The company has adopted restricted share incentive plans to attract and retain key employees[69]. - The company plans to continue monitoring the performance of cash-generating units to assess goodwill impairment[183].